247 related articles for article (PubMed ID: 16476324)
41. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
Kirtschig G; van Meurs T; van Doorn R
Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
[TBL] [Abstract][Full Text] [Related]
42. Topical 5% imiquimod in the treatment of lentigo maligna.
Wong JG; Toole JW; Demers AA; Musto G; Wiseman MC
J Cutan Med Surg; 2012; 16(4):245-9. PubMed ID: 22784516
[TBL] [Abstract][Full Text] [Related]
43. Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
Neumann I; Patalay R; Kaushik M; Timlin H; Daniel C
Eye (Lond); 2023 Feb; 37(3):408-414. PubMed ID: 35835989
[TBL] [Abstract][Full Text] [Related]
44. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
[TBL] [Abstract][Full Text] [Related]
45. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.
Buettiker UV; Yawalkar NY; Braathen LR; Hunger RE
Arch Dermatol; 2008 Jul; 144(7):943-5. PubMed ID: 18645150
[No Abstract] [Full Text] [Related]
46. Interventions for melanoma in situ, including lentigo maligna.
Tzellos T; Kyrgidis A; Mocellin S; Chan AW; Pilati P; Apalla Z
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010308. PubMed ID: 25526608
[TBL] [Abstract][Full Text] [Related]
47. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):407-412. PubMed ID: 35431054
[TBL] [Abstract][Full Text] [Related]
48. Videodermatoscopy of lentigo maligna treated with imiquimod.
Micali G; Lacarrubba F; Nardone B; Nasca MR
J Drugs Dermatol; 2008 Nov; 7(11):1077-80. PubMed ID: 19110742
[TBL] [Abstract][Full Text] [Related]
49. Case of large lentigo maligna melanoma of the scalp treated with 5% and 3.75% Imiquimod.
Rovesti M; Zucchi A; Feliciani C; Satolli F
An Bras Dermatol; 2021; 96(5):565-568. PubMed ID: 34261602
[TBL] [Abstract][Full Text] [Related]
50. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
51. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study.
Marsden JR; Fox R; Boota NM; Cook M; Wheatley K; Billingham LJ; Steven NM;
Br J Dermatol; 2017 May; 176(5):1148-1154. PubMed ID: 27714781
[TBL] [Abstract][Full Text] [Related]
52. Reply to: A practical guide on the use of imiquimod cream to treat lentigo maligna.
Muir J; McCormack C; De'Ambrosis B; Brown H; Kennedy D; Louie B; Smithers BM
Australas J Dermatol; 2022 May; 63(2):e197-e198. PubMed ID: 35262178
[No Abstract] [Full Text] [Related]
53. [Topical imiquimod as palliative therapy for extensive lentigo maligna on the cheek].
Cheikhrouhou H; Pouaha J; Claeys A; Truchetet F
Ann Dermatol Venereol; 2010 Feb; 137(2):142-4. PubMed ID: 20171439
[No Abstract] [Full Text] [Related]
54. Imiquimod 5% cream in occlusion, for the treatment of lentigo maligna: A new scheme of short cycles and the need for clinical trials.
Astorino S; Astorre P; Pasquini P; Di Nunno D; Pellegrini F; Paolino G
Dermatol Ther; 2019 Jan; 32(1):e12757. PubMed ID: 30285299
[No Abstract] [Full Text] [Related]
55. Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ.
Bartenjev MS; Isaković-Vidović S; Bartenjev I
Acta Dermatovenerol Croat; 2020 Jul; 28(1):34-37. PubMed ID: 32650849
[TBL] [Abstract][Full Text] [Related]
56. Treatment of lentigo maligna with topical 1% cidofovir.
Calista D
Br J Dermatol; 2007 Aug; 157(2):421-3. PubMed ID: 17596162
[No Abstract] [Full Text] [Related]
57. Lentigo maligna successfully treated with imiquimod.
du Plessis PJ
S Afr J Surg; 2007 May; 45(2):72. PubMed ID: 17674567
[No Abstract] [Full Text] [Related]
58. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
[TBL] [Abstract][Full Text] [Related]
59. Lymphoedema in patients with lentigo maligna treated with imiquimod: a long-term adverse effect.
Tio D; Kirtschig G; Hoekzema R; van Montfrans C
Br J Dermatol; 2018 Jun; 178(6):1441-1442. PubMed ID: 29274234
[No Abstract] [Full Text] [Related]
60. RECURRENT LENTIGO MALIGNA: CONSERVATIVE CONTINUOUS TREATMENT WITH IMIQUIMOD OR REPEATED SURGERY? A LONG-TERM FOLLOW-UP DERMOSCOPIC CASE STUDY.
De Giorgi V; Zuccaro B; Silvestri F; Venturi F; Colombo J; Trane L
Exp Oncol; 2023 Jun; 45(1):125-129. PubMed ID: 37417274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
